An FDA spokesperson told CNBC the agency will review the information, as it is set to vote on the vaccine’s emergency use authorization.
Unlike Pfizer and Moderna, Novavax isn’t mRNA-based — a component that was shown to be more effective at protecting against COVID-19. With a 90 percent efficacy rate, the potential fourth option for a vaccine was also clinically tested before the omicron variant swept across the U.S.
Before Novavax is rolled out, the FDA and CDC will have to authorize it.
